Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Dissertation
Immunopathological and Structural Alterations in Difficult to Control Asthma
TL;DR: New histopathological data that are associated with clinical control in asthma are provided, including a down-regulation of structures involved in airway narrowing and hyperreactivity, including airway smooth muscle, neuroendocrine epithelial cells, and nerve fibres.
Journal ArticleDOI
Asthma bronchiale – Verschreibung von Ambra grisea aufgrund eines auffallenden Lokalsymptoms
TL;DR: In this paper, aktuelle schulmedizinische und homopathischen Strategien bei der Behandung von Asthma bronchiale wird die homoopathische Behandlung eines Patienten mit thiser Erkrankung beschrieben.
Journal ArticleDOI
Asthma des Erwachsenen
TL;DR: In inhaled glucocorticosteroids remain the most effective anti-inflammatory treatment, but in addition innovative therapies such as anti-IgE therapy have been approved for subgroups with allergic and uncontrolled disease.
Journal Article
Xolair: A New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma
TL;DR: Xolair, administrated as an additional therapy, strongly improved the severe persistent IgE-mediated asthma and improved the patient life quality, by inducing positive effects on symp-toms and pulmonary function.
Book ChapterDOI
Asthma and Respiratory Allergic Disease
TL;DR: This chapter discusses the current state of the art in the understanding of allergic immunity and particularly the role of innate immunity as the major conduit linking the host response to the respirable environment.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.